Literature DB >> 10052683

Identification of major linear epitopes on the sp100 nuclear PBC autoantigen by the gene-fragment phage-display technology.

M Blüthner1, C Schäfer, C Schneider, F A Bautz.   

Abstract

Approximately 20-30% of sera from patients suffering from primary biliary cirrhosis contain autoantibodies against a nuclear protein termed sp100. By indirect cytoimmunofluorescence it was shown that the sp100 autoantigen is distributed in up to 20 dot-like structures per nucleus co-localizing with the so-called nuclear bodies. In western blots these sera react with a protein with an apparent molecular mass of 100kDa. By screening expression libraries with affinity-purified anti-sp100 antibodies we isolated a full-length sp100 cDNA whose sequence exactly matched the previously published sp100 sequence and encodes a protein of 481 amino acids with a deduced molecular mass of 53 kDa. In an attempt to determine immunoreactive regions on the sp100 antigen with the recently developed gene-fragment phage-display technology we were able to identify a stretch of sixteen amino acids (IKKEKPFSNSKVECQA) at position 296-311 as a major antigenic region (antigenic region 1) on the sp100-autoantigen. A second antigenic region (antigenic region 2) of twenty amino acids in length could be identified between amino acids 332-351 (EGSTDVDEPLEVFISAPRSE). By using immobilized synthetic peptides and various sp100-positive PBC patient sera the corresponding epitopes could be shown to be centered around epitope cores of six amino acids (SNSKVE, antigenic region 1) and nine amino acids (EPLEVFISA, antigenic region 2) respectively.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10052683     DOI: 10.3109/08916939908995970

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  9 in total

1.  Analysis of the autoimmune epitopes on human testicular NASP using recombinant and synthetic peptides.

Authors:  I N Batova; R T Richardson; E E Widgren; M G O'Rand
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  Selecting open reading frames from DNA.

Authors:  Paola Zacchi; Daniele Sblattero; Fiorella Florian; Roberto Marzari; Andrew R M Bradbury
Journal:  Genome Res       Date:  2003-05       Impact factor: 9.043

3.  Characterizing monoclonal antibody epitopes by filtered gene fragment phage display.

Authors:  Roberto Di Niro; Fortunato Ferrara; Tarcisio Not; Andrew R M Bradbury; Fernando Chirdo; Roberto Marzari; Daniele Sblattero
Journal:  Biochem J       Date:  2005-06-15       Impact factor: 3.857

Review 4.  Autoantigens in primary biliary cirrhosis.

Authors:  D E Jones
Journal:  J Clin Pathol       Date:  2000-11       Impact factor: 3.411

5.  Epitope-specific anti-nuclear antibodies are expressed in a mouse model of primary biliary cirrhosis and are cytokine-dependent.

Authors:  C-Y Yang; P S C Leung; G-X Yang; T P Kenny; W Zhang; R Coppel; G L Norman; A A Ansari; I R Mackay; H J Worman; M E Gershwin
Journal:  Clin Exp Immunol       Date:  2012-06       Impact factor: 4.330

6.  Comprehensive mapping of SARS-CoV-2 peptide epitopes for development of a highly sensitive serological test for total and neutralizing antibodies.

Authors:  Garima Kumar; Sarah Sterrett; Lucinda Hall; Edlue Tabengwa; Kazuhito Honjo; Michael Larimer; Randall S Davis; Paul A Goepfert; Benjamin M Larimer
Journal:  Protein Eng Des Sel       Date:  2022-02-17       Impact factor: 1.650

Review 7.  [Primary biliary liver cirrhosis and overlap syndrome. Diagnosis and therapy].

Authors:  C P Strassburg; M P Manns
Journal:  Internist (Berl)       Date:  2004-01       Impact factor: 0.743

Review 8.  The Fate of Speckled Protein 100 (Sp100) During Herpesviruses Infection.

Authors:  Mila Collados Rodríguez
Journal:  Front Cell Infect Microbiol       Date:  2021-02-01       Impact factor: 5.293

9.  Virtual interactomics of proteins from biochemical standpoint.

Authors:  Jaroslav Kubrycht; Karel Sigler; Pavel Souček
Journal:  Mol Biol Int       Date:  2012-08-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.